Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors

NCT03440450 is registered in ClinicalTrials.gov with Fujifilm Pharmaceuticals U.S.A., Inc. as lead sponsor.

NCT NCT03440450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03440450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 22, 2018
Completion date
March 31, 2027
Enrollment
90 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, biliary tract cancer